The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

ProstateJul 2, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Kohei Hashimoto, Kouji Izumi, Takashi Shima et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter randomized controlled trial investigated the impact of the lowest prostate-specific antigen (PSA) level before castration-resistant prostate cancer (CRPC) on the efficacy of abiraterone (ABI) and enzalutamide (ENZ) in metastatic CRPC. The study found that lower PSA levels were associated with improved docetaxel-free survival (DFS) in the ABI group (median 29.0 vs. 15.2 months, p=0.0209), but no significant differences were observed in the ENZ group.

Key findings

  • In the ABI arm, median DFS was 29.0 months for low PSA vs. 14.0 months for high PSA (p=0.0106).
  • Median time to PSA progression was undefined in the low PSA group vs. 4.7 months in the high PSA group (p=0.0443).
  • Radiographic progression-free survival was 39.5 months for low PSA vs. 9.8 months for high PSA (p=0.0243).
  • No significant differences in outcomes were found in the ENZ treatment arm.

Why it matters

Understanding the relationship between PSA levels and treatment outcomes can help clinicians better predict responses to therapies in metastatic CRPC, potentially guiding treatment decisions and patient management strategies.

Source

PubMed · PMID 42391446Free full text on PubMed Central

Published in Prostate. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.